Información:
Error:
ID
34563
Descripción
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).; ODM derived from: https://clinicaltrials.gov/show/NCT02480153
Link
https://clinicaltrials.gov/show/NCT02480153
Palabras clave
Versiones (1)
- 19/1/19 19/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
19 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Rheumatoid Arthritis NCT02480153
Eligibility Rheumatoid Arthritis NCT02480153
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT02480153
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
diagnosis of rheumatoid arthritis based on 2010 acr/eular criteria for at least 4 months.
boolean
ID.2
Item
at least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline.
boolean
ID.3
Item
hs-crp equal or greater than 8 mg/l.
boolean
ID.4
Item
must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose.
boolean
ID.5
Item
evidence of untreated or inadequately treated latent or active tb.
boolean
ID.6
Item
evidence of uncontrolled, clinically significant diseases, including moderate or severe heart failure (nyha class iii/iv) or malignancy in the previous 5 years.
boolean
ID.7
Item
history of infection requiring hospitalization or parenteral antimicrobial therapy within 6 months prior to first dose of study drug.
boolean
ID.8
Item
may have received no more than 2 doses of one biologic therapy (other than adalimumab or lymphocyte depleting therapy).
boolean
ID.9
Item
any second dmard must be washed out prior to the first study dose.
boolean